Response to the Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial"
- PMID: 31714317
- DOI: 10.1097/SLA.0000000000003676
Response to the Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial"
Conflict of interest statement
The authors report no conflicts of interest.
Comment on
-
Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial.Ann Surg. 2019 Jun;269(6):1025-1033. doi: 10.1097/SLA.0000000000003062. Ann Surg. 2019. PMID: 31082898 Clinical Trial.
-
Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial".Ann Surg. 2021 Aug 1;274(2):e194-e195. doi: 10.1097/SLA.0000000000003679. Ann Surg. 2021. PMID: 31714312 No abstract available.
References
-
- Troisi RI, Vanlander A, Giglio MC, et al. Inflow modulator in liver-transplant recipients with severe portal hypertension: a randomized trial. Ann Surg 2019; 269:1025–1033.
-
- Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53:1180–1189.
-
- Zou Z, Lin S, Li X, et al. Comment on “somatostatin as inflow modulator in liver-transplant recipients with severe portal hypertension: a randomized trial”. Ann Surg 2019; 270:1 e95–e96.
-
- Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39:280–282.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources